Pharmaceutical Manufacturing of Albendazole Tablets

The contract calls for the manufacture of FDA-compliant Albendazole Tablets, USP, in bottling configurations of two tablets per container, with strict adherence to a 24-month shelf-life requirement and military packaging standards to ensure durability and compliance under extreme conditions. The product must meet all applicable United States Pharmacopeia specifications and federal regulatory guidelines for safety, efficacy, and quality, with production and packaging executed to support long-term storage and distribution within the Department of Defense supply chain. The place of performance is designated as Fort Bragg, North Carolina, indicating centralized logistical integration with military medical operations. This is a subcontract issued under NAICS code 325412, which classifies it within the pharmaceutical and medicine manufacturing sector, and was posted on August 2, 2026, with a response deadline of August 10, 2026. The contracting organization is the Medical Supply Chain Pharm FSA under the Department of Defense, underscoring the critical nature of the product for military personnel and the need for secure, reliable, and high-standard pharmaceutical supply. The solicitation is part of DLA’s procurement system, accessible through the DIBBS portal, and expectations include full regulatory compliance, documented quality control, and packaging that meets ruggedized military specifications for field deployment.